Fig. 4

ctDNA gene mutations in 16 individual Fulvestrant users. 5 patients received second-line Fulvestrant treatment (a), and 11 patients received third-line or higher line Fulvestrant treatment (b). Dark red represents the most frequent mutated genes and dark blue represents the rarest mutations. If the mutated genes appeared at the same frequency, they are ranked in alphabetic order